Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
Portfolio Pulse from Vandana Singh
Johnson & Johnson reported Q3 earnings with a revenue and EPS beat, driven by strong cancer drug sales. The company revised its annual outlook to reflect the V-Wave acquisition. Despite the positive earnings, JNJ stock was down 1.29% in premarket trading.
October 15, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Johnson & Johnson's Q3 earnings beat expectations with strong sales in cancer drugs, but the stock fell 1.29% in premarket trading. The company revised its annual outlook due to the V-Wave acquisition.
Despite beating earnings expectations, JNJ's stock fell in premarket trading, possibly due to the revised annual outlook and costs associated with the V-Wave acquisition. The strong performance in cancer drug sales was a positive, but the market may have reacted to the lowered EPS guidance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100